Haptoglobin phenotypes, which one is better and when?

Clinical Laboratory

Volumn 52, Issue 1-2, 2006, Pages 29-35

  Zvi, Burbea ^a   Levy, Andrew P ^a  

^a RAMBAM MEDICAL CENTER   (Israel)

Author keywords

CKD; CVD; Diabetes; Dialysis; Haptoglobin; Hb clearance; Hp; Phenotypes

Indexed keywords

HAPTOGLOBIN; HEMOGLOBIN;

ANTIOXIDANT ACTIVITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CYTOKINE RELEASE; DIABETES MELLITUS; DIABETIC NEPHROPATHY; GERIATRIC PATIENT; HEMODIALYSIS; HEMODIALYSIS PATIENT; HEMOGLOBIN SYNTHESIS; HUMAN; INFECTION; MACROPHAGE ACTIVATION; MORBIDITY; MORTALITY; OXIDATIVE STRESS; PATHOGENESIS; PHENOTYPE; PHENOTYPIC VARIATION; PROTEIN BINDING; REVIEW; SURVIVAL TIME;

AGE FACTORS; CARDIOVASCULAR DISEASES; HAPTOGLOBINS; HEMOGLOBINS; HUMANS; KIDNEY FAILURE, CHRONIC; MODELS, BIOLOGICAL; RISK FACTORS;

EID: 32644463353     PISSN: 14336510     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (35)

1. Bowman BH. (1992) Haptoglobin, in Hepatic Plasma Proteins: Mechanisms of Function and Regulation (Bowman, BH, Ed.) pp159-167, Academic Press, San Diego, CA.
2. Langlois M, Delanghe J. Biological and clinical significance of haptoglobin polymorphism in humans. Clin Chem 1996; 42: 1589-600.
3. Gutteridge JMC. The antioxidant activity of haptoglobin towards haemoglobin-stimulated lipid peroxidation. Biochim Biophys Acta 1987;917: 219-23.
4. Miller Y, Altamentova S, Shaklai N. Oxidation of low-density lipoprotein by hemoglobin stems from a heme-initiated globin radical: antioxidant role of haptoglobin. Biochemistry 1997;36: 12189-98.
5. Jue DM, Shim BS, Kang YS. Inhibition of prostaglandin synthetase activity of sheep vesicular gland by human serum haptoglobin. Mol Cell Biochem 1983;51: 141-7.
6. Edwards DH, Griffith TM, Ryley HC, Henderson AH. Haptoglobin-haemoglobin complex in human plasma inhibits endothelium dependent relaxation: evidence that endothelium derived relaxing factor acts as a local autocoid. Cardiovasc Res 1986;20: 549-56.
7. Langlois M, Delanghe J, Philippe J, et al. Distribution of lymphocyte subsets in bone marrow and peripheral blood is associated with haptoglobin type. Eur J Clin Chem Clin Biochem 1997; 35: 199-205.
8. Cid MC, Grant DS, Hoffman GS, Auerbach R, Fauci AS, Kleinman HK. Identification of haptoglobin as an angiogenic factor in sera from patients with systemic vasculitis. J Clin Invest 1993; 91: 977-85.
9. Burbea Z, Nakhoul F, Rosenberg S, Zoabi R, Skorecki K, Hochberg I, Miller-Lotan R, Benchetrit S, Weissgarten J, Knecht A, Tovbin D, Levy NS, Levy AP. Role of haptoglobin phenotype in end-stage kidney disease. Nephron Exp Nephrol 2004;97(2): e71-6.
10. Bowman BH, Kurosky A. Haptoglobin: the evolutionary product of duplication, unequal crossing over, and point mutation. Adv Human Genet 1982; 12: 189-261.
11. Kristiansen M, Graversen JH, Jacobsen C, Sonne O, Hoffman HJ, Law SK, Moestrup SK. Identification of the hemoglobin scavenger receptor. Nature 2001; 409: 198-201.
12. Ziouzenkova O, Asatryan L, Akmal M, Tetta C, Wratten ML, Loseto-Wich G, Jurgens G, Heinecke J, Sevanian A. Oxidative cross-linking of ApoB100 and hemoglobin results in low density lipoprotein modification in blood: Relevance to atherogenesis caused by hemodialysis. J Biol Chem 1999; 274: 18916-18924.
13. Hochberg I, Roguin A, Nikolsky E, Chandersashekhar PV, Cohen S, Levy AP. Haptoglobin phenotype and coronary artery collaterals in diabetic patients. Atherosclerosis 2002; 161: 441-446.
14. Melamed-Frank M, Lache O, Enav BI, Szafranek T, Levy NS, Rickis RM, Levy AP. Structure-function analysis of the antioxidant properties of haptoglobin. Blood 2001; 98: 3693-3698.
15. Levy AP. Genetics of diabetic cardiovascular disease: identification of a major susceptibility gene. Acta Diabetol 2003; 40 Suppl 2: S330-3.
16. Levy AP, Hochberg I, Jablonski K, Resnick HE, Best L, Lee E, Howard BV. Haptoglobin phenotype is an independent risk factor for cardiovascular disease in individuals with diabetes: The Strong Heart Study. J Am Coll Card 2002; 40: 1984-1990.
17. Langlois M, Delanghe J, De Buyzere M, Bernard D, Ouyang J. Effect of haptoglobin on the metabolism of vitamin C. Am J Clin Nutr 1997; 66: 606-10.
18. Asleh R, Guetta J, Kalet-Litman S, Miller-Lotan R, Levy AP. Genetically determined heterogeneity in hemoglobin scavenging and susceptibility to diabetic cardiovascular disease. Circ Res 2005; 96: 435-441.
19. Quaye IK, Ekuban FA, Goka BQ, Adabayeri V, Kurtzhals JA, Gyan B, Ankrah NA, Hviid L, Akanmori BD. Haptoglobin 1-1 is associated with susceptibility to severe Plasmodium falciparum malaria. Trans R Soc Trop Med Hyg 2000; 94(2): 216-219.
20. Beiguelman B, Alves FP, Moura MM, Engracia V, Nunes AC, Heckmann MI, Ferreira RG, da Silva LH, Camargo EP, Krieger H. The association of genetic markers and malaria infection in the Brazilian Western Amazonian region. Mem Inst Oswaldo Cruz 2003; 98(4): 455-60.
21. Roguin A, Ribichini F, Ferraro V, Matullo G, Herer p, Wijns W, Levy AP. Haptoglobin phenotype and the risk of restenosis after coronary artery stent implantation. Am J Cardiol 2002;89: 806-810.
22. Delanghe J, Langlois M, Duprez D, De Buyzere M, Clement D. Haptoglobin polymorphism and peripheral arterial occlusive disease. Atherosclerosis 1999; 145(2): 287-92.
23. De Bacquer D, De Backer G, Langlois M, Delanghe J, Kesteloot H, Kornitzer M. Haptoglobin polymorphism as a risk factor for coronary heart disease mortality. Atherosclerosis 2001; 157(1): 161-6.
24. Burbea Z, Nakhoul F, Zoabi R, Hochberg I, Levy NS, Benchetrit S, Weissgarten J, Tovbin D, Knecht A, Iaina A, Herman M, Kristal B, Levy AP. Haptoglobin phenotype as a predictive factor of mortality in diabetic hemodialysis patients. Ann Clin Biochem 2004; 41(Pt 6): 469-73.
25. Sadrzadeh SM, Graf E, Panter SS, Hallaway PE, Eaton JW. Hemoglobin. A biologic Fenton reagent. J Biol Chem 1984; 259(23): 14354-6.
26. Campian JL, Qian M, Gao X, Eaton JW. Oxygen tolerance and coupling of mitochondrial electron transport. J Biol Chem 2004; 279(45): 46580-7.
27. Tsemakhovich VA, Bamm VV, Shaklai M, Shaklai N. Vascular damage by unstable hemoglobins: the role of heme-depleted globin. Arch Biochem Biophys 2005; 15: 436(2): 307-15.
28. Everse J, Hsia N. The toxicities of native and modified hemoglobins. Free Radic Biol Med 1997; 22(6): 1075-99.
29. Valko M, Morris H, Cronin MT. Metals, toxicity and oxidative stress. Curr Med Chem 2005; 12(10): 1161-208.
30. Bamm VV, Tsemakhovich VA, Shaklai M, Shaklai N. Haptoglobin phenotypes differ in their ability to inhibit heme transfer from hemoglobin to LDL. Biochemistry 2004; 43(13): 3899-906.
31. Nevo S, Tatarsky I. Serum haptoglobin types and leukemia. Hum Genet 1986; 73: 240-244.
32. US Renal Data System: USRDS 2004 Annual Data Report: Bethesda, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2004.
33. Roguin A, Hochberg I, Nikolsky E, et al. Haptoglobin phenotype as a predictor of restenosis after percutaneous transluminal coronary angioplasty. Am J Cardiol 2001; 87: 330-332.
34. Nakhoul FM, Zoabi R, Kantor Y, et al. Haptoglobin phenotype and diabetic nephropathy. Diabetologia 2001; 44: 602-604.
35. Hamad M, Awadallah S. Age group-associated variations in the pattern of Hp type distribution in Jordanians. Clin Chim Acta 2003; 300: 75-81.